Provided by Tiger Trade Technology Pte. Ltd.

Syndax Pharmaceuticals

13.66
-2.8900-17.46%
Volume:4.74M
Turnover:65.42M
Market Cap:1.22B
PE:-5.44
High:14.72
Open:14.61
Low:13.50
Close:16.55
52wk High:25.59
52wk Low:12.99
Shares:89.30M
Float Shares:80.30M
Volume Ratio:4.11
T/O Rate:5.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5100
EPS(LYR):-3.2949
ROE:-255.93%
ROA:-18.67%
PB:80.79
PE(LYR):-4.15

Loading ...

Syndax Pharmaceuticals Stock Plunges. a Failed Trial Deals Blow to Growth Plans.

Dow Jones
·
Yesterday

Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says

MT Newswires Live
·
Yesterday

Syndax Pharmaceuticals Down over 17%, on Pace for Largest Percent Decrease Since May 2025

Dow Jones
·
Yesterday

Syndax valuation unchanged after trial miss, says H.C. Wainwright

TIPRANKS
·
Yesterday

Syndax selloff brings attractive entry point, says Citi

TIPRANKS
·
Yesterday

BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Syndax Pharmaceuticals Price Target Maintained with a $38.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Syndax price target lowered to $23 from $26 at BofA

TIPRANKS
·
Yesterday

Stocks to Watch: Syndax Pharmaceuticals, FormFactor, Navitas Semiconductor

Dow Jones
·
Yesterday

Syndax Says Mid-Stage Trial of Lung Disease Treatment Fails Main Goal, Ends Development

Reuters
·
Yesterday

Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint

TIPRANKS
·
Yesterday

Syndax to end development of axatilimab in idiopathic pulmonary fibrosis

TIPRANKS
·
Yesterday

Syndax sinks 15% to $14 after idiopathic pulmonary fibrosis miss

TIPRANKS
·
Yesterday

Syndax Axatilimab Misses Primary Endpoint in Phase 2 IPF Trial, Drops Further Development in Indication

Reuters
·
Yesterday

Syndax Announces Topline Results from Maxpire Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
Yesterday

Syndax Pharmaceuticals - Axatilimab Continues in Multiple Cgvhd Trials with Results Expected Later This Year and Early 2028

THOMSON REUTERS
·
Yesterday

Syndax Pharmaceuticals - Maxpire Phase 2 Trial of Axatilimab in Ipf Does not Meet Primary Endpoint

THOMSON REUTERS
·
Yesterday

Syndax Pharmaceuticals - Will not Pursue Further Development of Axatilimab in Ipf

THOMSON REUTERS
·
Yesterday

Syndax Pharmaceuticals - Axatilimab Well Tolerated with no New Safety Signals in Maxpire Trial

THOMSON REUTERS
·
Yesterday

Retail Investors Return to Tech Stocks: JPMorgan Reports NVIDIA Led Last Week's Buying at $834 Million, Chip and Storage Stocks Favored

Stock News
·
Oct 08